{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:47:48Z","timestamp":1782773268458,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04374-8","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:24:16Z","timestamp":1778048656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Germline HLA-I genotypes predict pathologic response and survival outcomes in esophageal cancer patients undergoing neoadjuvant immunochemotherapy: a retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Willis Wasonga","family":"Omindo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyou","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"1","key":"4374_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40364-024-00718-2","volume":"13","author":"W Jin","year":"2025","unstructured":"Jin W, Huang K, Ding Z, Zhang M, Li C, Yuan Z, et al. Global, regional, and national burden of esophageal cancer: a systematic analysis of the Global Burden of Disease Study 2021. Biomark Res. 2025;13(1):3.","journal-title":"Biomark Res"},{"issue":"2","key":"4374_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/wjon1254","volume":"11","author":"EO Then","year":"2020","unstructured":"Then EO, Lopez M, Saleem S, Gayam V, Sunkara T, Culliford A, et al. Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis. World J Oncol. 2020;11(2):55\u201364.","journal-title":"World J Oncol"},{"issue":"9","key":"4374_CR3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090\u20138.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4374_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrgastro.2015.145","volume":"12","author":"C Weber","year":"2015","unstructured":"Weber C. Oesophageal cancer: Neoadjuvant chemoradiotherapy and surgery superior to surgery alone. Nat Rev Gastroenterol Hepatol. 2015;12(9):489.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"4374_CR5","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.21037\/jtd-2025-215","volume":"17","author":"M Wang","year":"2025","unstructured":"Wang M, Wei D, Cui Z, Zhou Y, Yin C, Zhou Z, et al. Evaluation of the efficacy and safety of neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma. J Thorac Dis. 2025;17(3):1711\u201322.","journal-title":"J Thorac Dis"},{"key":"4374_CR6","doi-asserted-by":"publisher","first-page":"1108213","DOI":"10.3389\/fimmu.2023.1108213","volume":"14","author":"H Qin","year":"2023","unstructured":"Qin H, Liu F, Zhang Y, Liang Y, Mi Y, Yu F, et al. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis. Front Immunol. 2023;14:1108213.","journal-title":"Front Immunol"},{"issue":"2","key":"4374_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.athoracsur.2008.11.001","volume":"87","author":"JM Donahue","year":"2009","unstructured":"Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009;87(2):392\u20139.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"4374_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4291\/wjgp.v5.i3.322","volume":"5","author":"N Uemura","year":"2014","unstructured":"Uemura N, Kondo T. Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer. World J Gastrointest Pathophysiol. 2014;5(3):322\u201334.","journal-title":"World J Gastrointest Pathophysiol"},{"key":"4374_CR9","doi-asserted-by":"publisher","first-page":"998620","DOI":"10.3389\/fimmu.2022.998620","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Li S, Liu T, Chen J, Dang J. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis. Front Immunol. 2022;13:998620.","journal-title":"Front Immunol"},{"issue":"11","key":"4374_CR10","doi-asserted-by":"publisher","first-page":"e2239778","DOI":"10.1001\/jamanetworkopen.2022.39778","volume":"5","author":"F Ge","year":"2022","unstructured":"Ge F, Huo Z, Cai X, Hu Q, Chen W, Lin G, et al. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(11):e2239778\u2013e.","journal-title":"JAMA Netw Open"},{"key":"4374_CR11","doi-asserted-by":"crossref","unstructured":"Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1\/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel). 2021;14(1).","DOI":"10.3390\/cancers14010109"},{"key":"4374_CR12","doi-asserted-by":"crossref","unstructured":"Wang C, Xiong C, Hsu Y-C, Wang X, Chen L. Human leukocyte antigen (HLA) and cancer immunotherapy: HLA-dependent and-independent adoptive immunotherapies. Annals Blood. 2020;5.","DOI":"10.21037\/aob-20-27"},{"issue":"6375","key":"4374_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582\u20137.","journal-title":"Science"},{"key":"4374_CR14","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3389\/fimmu.2017.00832","volume":"8","author":"NB Crux","year":"2017","unstructured":"Crux NB, Elahi S. Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol. 2017;8:832.","journal-title":"Front Immunol"},{"issue":"5","key":"4374_CR15","doi-asserted-by":"publisher","first-page":"e011278","DOI":"10.1136\/jitc-2024-011278","volume":"13","author":"Y Li","year":"2025","unstructured":"Li Y, Yeong J, Fox BA, Sun C. Asia\u2019s emergence in cancer immunotherapy: challenges and opportunities. J Immunother Cancer. 2025;13(5):e011278.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4374_CR16","doi-asserted-by":"publisher","first-page":"e1010337","DOI":"10.1371\/journal.ppat.1010337","volume":"18","author":"JR Habel","year":"2022","unstructured":"Habel JR, Nguyen AT, Rowntree LC, Szeto C, Mifsud NA, Clemens EB, et al. HLA-A* 11: 01-restricted CD8\u2009+\u2009T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people. PLoS Pathog. 2022;18(3):e1010337.","journal-title":"PLoS Pathog"},{"issue":"8","key":"4374_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00262-024-03729-y","volume":"73","author":"M Shen","year":"2024","unstructured":"Shen M, Chen S, Han X, Hao Y, Wang J, Li L, et al. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations. Cancer Immunol Immunother. 2024;73(8):150.","journal-title":"Cancer Immunol Immunother"},{"key":"4374_CR18","doi-asserted-by":"crossref","unstructured":"Ade CM, Sporn MJ, Das S, Yu Z, Hanada KI, Qi YA et al. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics. J Immunother Cancer. 2023;11(9).","DOI":"10.1136\/jitc-2023-007097"},{"issue":"1","key":"4374_CR19","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8(1):1738.","journal-title":"Nat Commun"},{"issue":"4","key":"4374_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10388-024-01072-w","volume":"21","author":"T Makino","year":"2024","unstructured":"Makino T, Miyata H, Yasuda T, Kitagawa Y, Muro K, Park JH, et al. A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma. Esophagus. 2024;21(4):447\u201355.","journal-title":"Esophagus"},{"issue":"3","key":"4374_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1078-0432.CCR-1086-3","volume":"10","author":"H Yamaguchi","year":"2004","unstructured":"Yamaguchi H, Tanaka F, Ohta M, Inoue H, Mori M. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response. Clin Cancer Res. 2004;10(3):890\u20136.","journal-title":"Clin Cancer Res"},{"key":"4374_CR22","doi-asserted-by":"crossref","unstructured":"Sewastianik T, Roy C, Gormally MV, Montesion M, Halvey P, Jindal A et al. Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance. J Immunother Cancer. 2025;13(9).","DOI":"10.1136\/jitc-2025-012435"},{"issue":"1","key":"4374_CR23","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41467-024-45361-5","volume":"15","author":"J Han","year":"2024","unstructured":"Han J, Dong Y, Zhu X, Reuben A, Zhang J, Xu J, et al. Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nat Commun. 2024;15(1):1199.","journal-title":"Nat Commun"},{"issue":"4","key":"4374_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Reviews Clin Oncol. 2021;18(4):215\u201329.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"4374_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","volume":"41","author":"L Lybaert","year":"2023","unstructured":"Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, et al. Challenges in neoantigen-directed therapeutics. Cancer Cell. 2023;41(1):15\u201340.","journal-title":"Cancer Cell"},{"key":"4374_CR26","first-page":"478","volume":"5","author":"A Puangpetch","year":"2014","unstructured":"Puangpetch A, Koomdee N, Chamnanphol M, Jantararoungtong T, Santon S, Prommas S, et al. HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity. Front Genet. 2014;5:478.","journal-title":"Front Genet"},{"issue":"5\u20136","key":"4374_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00251-024-01349-5","volume":"76","author":"S Tao","year":"2024","unstructured":"Tao S, You X, Chen N, Dong L, Zhao S, He Y, et al. The characteristic of HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DRB3\/4\/5, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 alleles in Zhejiang Han population. Immunogenetics. 2024;76(5\u20136):305\u201314.","journal-title":"Immunogenetics"},{"key":"4374_CR28","doi-asserted-by":"publisher","first-page":"944872","DOI":"10.3389\/fimmu.2022.944872","volume":"13","author":"S Pagliuca","year":"2022","unstructured":"Pagliuca S, Gurnari C, Rubio MT, Visconte V, Lenz TL. Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Front Immunol. 2022;13:944872.","journal-title":"Front Immunol"},{"issue":"2","key":"4374_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97\u2013111.","journal-title":"Nat Rev Immunol"},{"key":"4374_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04374-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04374-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04374-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:29:47Z","timestamp":1782772187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04374-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4374"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04374-8","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval No. 2019-S910).All participants provided written informed consent for the use of their clinical and genetic data. All study procedures were conducted in accordance with relevant institutional guidelines and regulations and complied with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}